On December 18, 2025, in San Carlos, California, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) disclosed the approval of inducement stock options for four new non-executive employees. The options cover a total of 43,150 shares of the company's common stock. Iovance is a biotech firm specializing in creating and providing innovative polyclonal tumor infiltrating lymphocyte ("TIL") treatments for cancer patients.